Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Lauritzen

Showing results (41-50 of 132) with videos related to

Pageof 14
Sort By:
Diabetes|August 1, 1985
Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathyT Lauritzen, K Frost-Larsen, H W Larsen, et al.
Acta Endocrinologica|February 1, 1984
Absorption of soluble and isophane semi-synthetic human and porcine insulin in insulin-dependent diabetic subjectsS Pramming, T Lauritzen, B Thorsteinsson, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|August 30, 2007
Are lifestyle changes achieved after participation in a screening programme for Type 2 diabetes? The ADDITION Study, DenmarkK S Mai, A Sandbaek, K Borch-Johnsen, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1990
Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indicesJ O Jørgensen, N Møller, T Lauritzen, et al.
Diabetologia|February 23, 2011
HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), DenmarkT Lauritzen, A Sandbaek, M V Skriver, et al.
Diabetologia|September 15, 2004
Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithmsJ O Christensen, A Sandbaek, T Lauritzen, et al.
Diabetologia|August 11, 2010
HbA1c as predictor of all-cause mortality in individuals at high risk of diabetes with normal glucose tolerance, identified by screening: a follow-up study of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION), DenmarkM V Skriver, K Borch-Johnsen, T Lauritzen, et al.
Diabetes, Obesity & Metabolism|October 10, 2006
Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetesJ-W Chen, T Lauritzen, A Bojesen, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|October 8, 2013
Circadian variation in the pharmacokinetics of steady state continuous subcutaneous infusion of growth hormone in adult growth hormone deficient patientsJ Janukonyté, T Parkner, T Lauritzen, et al.
British Medical Journal (Clinical Research Ed.)|July 17, 1982
Absorption of isophane (NPH) insulin and its clinical implicationsT Lauritzen, S Pramming, E A Gale, et al.
Pageof 14

Showing results (41-50 of 132) with videos related to

Sort By:
Pageof 14
Diabetes|August 1, 1985
Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathyT Lauritzen, K Frost-Larsen, H W Larsen, et al.
Acta Endocrinologica|February 1, 1984
Absorption of soluble and isophane semi-synthetic human and porcine insulin in insulin-dependent diabetic subjectsS Pramming, T Lauritzen, B Thorsteinsson, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|August 30, 2007
Are lifestyle changes achieved after participation in a screening programme for Type 2 diabetes? The ADDITION Study, DenmarkK S Mai, A Sandbaek, K Borch-Johnsen, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1990
Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indicesJ O Jørgensen, N Møller, T Lauritzen, et al.
Diabetologia|February 23, 2011
HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), DenmarkT Lauritzen, A Sandbaek, M V Skriver, et al.
Diabetologia|September 15, 2004
Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithmsJ O Christensen, A Sandbaek, T Lauritzen, et al.
Diabetologia|August 11, 2010
HbA1c as predictor of all-cause mortality in individuals at high risk of diabetes with normal glucose tolerance, identified by screening: a follow-up study of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION), DenmarkM V Skriver, K Borch-Johnsen, T Lauritzen, et al.
Diabetes, Obesity & Metabolism|October 10, 2006
Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetesJ-W Chen, T Lauritzen, A Bojesen, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|October 8, 2013
Circadian variation in the pharmacokinetics of steady state continuous subcutaneous infusion of growth hormone in adult growth hormone deficient patientsJ Janukonyté, T Parkner, T Lauritzen, et al.
British Medical Journal (Clinical Research Ed.)|July 17, 1982
Absorption of isophane (NPH) insulin and its clinical implicationsT Lauritzen, S Pramming, E A Gale, et al.
Pageof 14